Jump to main content
Jump to site search


Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

Author affiliations

Abstract

Trastuzumab (Herceptin®) is an FDA-approved therapeutic antibody currently employed in the treatment of metastatic stages of breast cancer. Herein, we propose a simple, fast and cost-effective methodology to conjugate trastuzumab with 22-mer 5′ thiol-modified oligonucleotides using a bifunctional crosslinker. The conjugates were successfully characterized by MALDI-ToF MS and SDS-PAGE, obviating the need for enzymatic digestion and difficult chromatographic separations. Furthermore, ELISA was performed to ensure that trastuzumab activity is not affected by oligonucleotide conjugation.

Graphical abstract: Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

Back to tab navigation

Supplementary files

Publication details

The article was received on 03 Sep 2017, accepted on 09 Oct 2017 and first published on 09 Oct 2017


Article type: Paper
DOI: 10.1039/C7OB02216F
Citation: Org. Biomol. Chem., 2017, Advance Article
  •   Request permissions

    Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

    A. M. Carvalho, A. Manicardi, C. V. Montes, S. B. Gunnoo, R. J. Schneider and A. Madder, Org. Biomol. Chem., 2017, Advance Article , DOI: 10.1039/C7OB02216F

Search articles by author

Spotlight

Advertisements